KBKelly Bruton

Kelly Bruton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kelly Bruton has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Manel Jordana

    Schroeder Allergy & Immunology Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    7 shared publications
  • Susan Waserman

    Schroeder Allergy and Immunology Research Institute, Faculty of Health Sciences, McMaster University

    7 shared publications
  • Joshua F. E. Koenig

    McMaster Immunology Research Centre, Schroeder Allergy and Immunology Research Institute, Department of Medicine, Faculty of Health Sciences, McMaster University

    5 shared publications
  • Siyon Gadkar

    Schroeder Allergy & Immunology Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    5 shared publications
  • Tina D. Walker

    Schroeder Allergy & Immunology Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

    5 shared publications
  • Rodrigo Jiménez-Saiz

    Department of Immunology Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS‐Princesa) Madrid Spain

    4 shared publications

Latest Publications

  • Pathogenic IgE-fated memory B cell responses retain functional plasticity

    by Kelly Bruton, Allyssa Phelps, Atai Ariaz, Allison Fang, Tina D. Walker, Jianping Wen, Sharon S. Khavkine-Binstock, Danielle Della Libera, Olivia Mann-Delany, Niels Peter H. Knudsen, et al.

    Long-lived immunoglobulin E (IgE) responses against innocuous environmental and dietary antigens (Ags) are maintained by an IgG1-dominant memory B cell (MBC) compartment primed for interleukin-4 (IL-4) responsiveness. The plasticity of the MBC compartment destined for IgE class switch recombination remains poorly understood. In this work, we report critical IL-4 and IL-13 dependency for the pathogenic IgE fate of type 2–polarized MBCs in allergy. Initiation of a recall response in the absence of IL-4 and IL-13 signaling diminished the type 2 MBC phenotype in mice and humans. This permitted the emergence of long-lived Ag-specific IgG2c + MBCs in mice. The divergence to a type 1–like response was dependent on interferon-γ signaling and arose from both unswitched and class-switched Ag-specific B cells in vivo. This reprogrammed fate was sustained even beyond therapeutic intervention, revealing fundamental insights into the plasticity of the allergen-specific recall response.


  • Open Access

    Allergic Reactivity and Memory Occur Independently of Sequential Switching Through IgG1

    by Joshua F. E. Koenig, Adam K. Wade‐Vallance, Rodrigo Jiménez‐Saiz, Kelly Bruton, Siyon Gadkar, Emily Grydziuszko, Tina D. Walker, Melissa E. Gordon, Amy E. Gillgrass, Justin J. Taylor, et al.

    Allergic reactions to foods are primarily driven by allergen‐binding immunoglobulin (Ig)E antibodies. IgE‐expressing cells can be generated through direct switching from IgM to IgE or a sequential class switching pathway where activated B cells first switch to an intermediary isotype, most frequently IgG1, and then to IgE. It has been proposed that sequential class switch recombination is involved in augmenting the severity of allergic reactions, generating high affinity IgE, differentiation of IgE plasma cells, and in holding the memory of IgE responses. We directly tested these possibilities by comparing the allergic immunity of wild‐type and IgG1‐deficient (hMT) mice. We found that sequential switching through IgG1 was not required to maintain the binding capacity of IgE nor for its ability to promote degranulation and elicit anaphylaxis against bona fide food allergens. Furthermore, the absence of sequential switching modestly impacted IgE affinity and clinical reactivity against hapten antigens, suggesting that the nature of the antigen impacts the requirement for sequential switching. At a cellular level, the capacity to undergo sequential switching through IgG1 provided no competitive advantage for subsequent IgE expression among germinal center B cells or plasma cells. Furthermore, the recall of allergic immunity at memory timepoints was preserved in the absence of sequential switching through IgG1, a finding that corresponded with intact type 2 memory B cell polarization. Together, these data demonstrate that sequential switching through IgG1 is redundant in sensitization, anaphylaxis, and the persistence of allergy, ultimately revealing that IgE derived from any switching source should be targeted by novel therapeutics seeking to ameliorate allergic diseases.


  • Top Cited Papers

    Type 2–polarized memory B cells hold allergen-specific IgE memory

    by Joshua F. E. Koenig, Niels Peter H. Knudsen, Allyssa Phelps, Kelly Bruton, Ilka Hoof, Gitte Lund, Danielle Della Libera, Anders Lund, Lars Harder Christensen, David R. Glass, et al.

    Allergen-specific immunoglobulin E (IgE) antibodies mediate pathology in diseases such as allergic rhinitis and food allergy. Memory B cells (MBCs) contribute to circulating IgE by regenerating IgE-producing plasma cells upon allergen encounter. Here, we report a population of type 2–polarized MBCs defined as CD23 hi , IL-4Rα hi , and CD32 low at both the transcriptional and surface protein levels. These MBC2s are enriched in IgG1- and IgG4-expressing cells while constitutively expressing germline transcripts for IgE. Allergen-specific B cells from patients with allergic rhinitis and food allergy were enriched in MBC2s. Furthermore, MBC2s generated allergen-specific IgE during sublingual immunotherapy, thereby identifying these cells as a major reservoir for IgE. The identification of MBC2s provides insights into the maintenance of IgE memory, which is detrimental in allergic diseases but could be beneficial in protection against venoms and helminths.


  • Open Access

    Pathogenic IgE-fated memory B cell responses retain functional plasticity

    by Kelly Bruton, Allyssa Phelps, Atai Ariaz, Allison Fang, Tina D. Walker, Jianping Wen, Sharon S. Khavkine-Binstock, Danielle Della Libera, Olivia Mann-Delany, Niels Peter H. Knudsen, et al.

    Long-lived immunoglobulin (Ig) E responses against innocuous environmental and dietary antigens (Ags) are maintained by an IgG1-dominant memory B cell (MBC) compartment primed for IL-4 responsiveness. The plasticity of the MBC compartment destined for IgE class switch recombination (CSR), however, remains poorly understood. In this work, we report a critical IL-4/IL-13 dependency for the pathogenic IgE fate of type 2-polarized MBCs. Initiating a recall response in the absence of IL-4/IL-13 signaling diminished the type 2 MBC phenotype in mice and humans and, in mice, permitted the emergence of long-lived Ag-specific IgG2c + MBCs. The divergence to a type 1-like response was dependent on IFN-γ signaling and arose from both unswitched and class-switched Ag-specific B cells in vivo . This reprogrammed fate was sustained even beyond therapeutic intervention, revealing fundamental insight into the plasticity of the allergen-specific MBC response. One Sentence Summary: B cell responses to allergens can be reprogrammed away from a pathogenic fate through IL-4/IL-13 signaling blockade.


  • Open Access

    Sequential Switching Through IgG1 is Redundant for Allergic Reactivity and Memory to Allergens

    by Joshua F.E. Koenig, Adam Wade-Vallance, Rodrigo Jiménez-Saiz, Kelly Bruton, Siyon Gadkar, Emily Grydziuszko, Tina Walker, Melissa E. Gordon, Susan Waserman, Manel Jordana

    Allergic reactions to foods are driven by allergen-binding immunoglobulin (Ig)E antibodies. IgE- expressing cells can be generated through a sequential class switching pathway where activated B cells first switch to an intermediary isotype, most frequently IgG1, and then to IgE. It has been proposed that sequential class switch recombination is important in generating high affinity IgE, augmenting anaphylactic reactions, and in holding the memory of IgE responses. Here, we observed surprising redundancy of sequential switching through IgG1 for the functional affinity of the IgE repertoire against multiple food allergens as well as for the ability of IgE to elicit anaphylaxis. We further found that sequential switching via IgG1 was irrelevant for allergic memory. These results indicate that allergen-specific IgG1 B cells are redundant in sensitization, anaphylaxis, and food allergy persistence, thereby implicating other switching pathways as important considerations in the development of therapeutics for allergic diseases.

  • Open Access

    A Distinct Phenotype of Polarized Memory B cell holds IgE Memory

    by Joshua F.E. Koenig, Niels Peter H Knudsen, Allyssa Phelps, Kelly Bruton, Ilka Hoof, Gitte Lund, Danielle Della Libera, Anders Lund, Lars Harder Christensen, David R. Glass, et al.

    Allergen-specific IgE antibodies mediate allergic pathology in diseases such as allergic rhinitis and food allergy. Memory B cells (MBCs) contribute to circulating IgE by regenerating IgE-producing plasma cells upon allergen encounter. We report a population of type 2 polarized MBCs defined as CD23 hi , IL-4Rα hi , CD32 low at the transcriptional and surface protein levels. These “MBC2s” are enriched in IgG1 and IgG4-expressing cells, while constitutively expressing germline transcripts for IgE. Allergen-specific B cells from patients with allergic rhinitis and food allergy were enriched in MBC2s. MBC2s generated allergen specific-IgE during sublingual immunotherapy, thereby identifying these cells as the primary reservoir of IgE. The identification of MBC2s provides insights into the maintenance of IgE memory, which is detrimental in allergic diseases, but which could be beneficial in protection against venoms and helminths. One-Sentence Summary: Identification of a novel memory B cell subset which holds allergen specific IgE memory.


  • Open Access

    Peanut allergy: Beyond the oral immunotherapy plateau

    by Kelly Bruton, Paul Spill, Derek K. Chu, Susan Waserman, Manel Jordana

    Background: There are a lack of disease‐modifying treatments for peanut allergy, which is lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective treatments, though its efficacy is consistently undermined by the risk of adverse reactions and meager sustained effects.Aim: This review discusses the current state of oral immunotherapy, its strengths and limitations, and the future of therapeutics for the treatment of peanut allergy.Conclusion: The persistence of peanut allergy is currently attributed to reservoirs of peanut‐specific memory B cells and Th2 cells, though the cellular and molecular interplay that facilitates the replenishment of peanut‐specific IgE remains elusive. Uncovering these events will prove critical for identification of novel targets as we forge ahead to a new age of peanut allergy treatment with biotherapeutics.


  • Interrupting reactivation of immunologic memory diverts the allergic response and prevents anaphylaxis

    by Kelly Bruton, Paul Spill, Shabana Vohra, Owen Baribeau, Saba Manzoor, Siyon Gadkar, Malcolm Davidson, Tina D. Walker, Joshua F.E. Koenig, Yosef Ellenbogen, et al.


  • Open Access

    TAK1 ng aim at mechanisms of allergic inflammation: contribution of TAK1 activity in allergen‐mediated mast cell activation

    by Colton J. F. Watson, Aindriu R. R. Maguire, Melissa M. Rouillard, Robert W. E. Crozier, Michael Yousef, Kelly M. Bruton, Val A. Fajardo, Adam J. MacNeil

    Allergic inflammatory disorders are at epidemic levels worldwide. Mast cells drive this inappropriate immune response via release of a variety of pro‐inflammatory mediators in response to environmental cues detected by the IgE‐FcɛRI complex, but the contributing molecular mechanisms are not fully understood. Transforming growth factor β‐activated kinase 1 (TAK1) is a known participant in related signaling through both the MAPK and NFκB pathways; however, the role of TAK1 in IgE‐FcɛRI mediated signaling and resultant allergic inflammation remains unknown. This study was carried out to assess the role of TAK1 in IgE‐mediated mast cell activation and to determine the effect its inhibition would have on the severity of an allergic inflammatory response. Assessment of the role of TAK1 was conducted by exploiting the characterized inhibitory function of 5Z‐7‐oxozeaenol (OZ), a resorcylic acid lactone established to be an ATP‐competitive selective inhibitor of TAK1. Bone marrow‐derived mast cells were sensitized with allergen‐specific IgE and treated with the corresponding allergen for various times in the presence or absence of OZ. Mast cell signaling was measured by western blotting, induced gene expression by qPCR, pro‐inflammatory mediator release by ELISA, mast cell degranulation by β‐hexosaminidase release assay, and calcium mobilization alterations via Indo‐1 based spectrofluorometry. We detect novel activation of TAK1 at Ser412 in response to IgE‐mediated activation under SCF‐c‐kit potentiation in a mast cell‐driven response characteristic of allergic inflammation, which is potently blocked by TAK1 inhibitor OZ. We therefore interrogated the role of TAK1 in a series of mast cell mediator responses using IgE‐sensitized murine bone marrow‐derived mast cells, stimulated with allergen under several TAK1 inhibition strategies. TAK1 inhibition resulted in significant impairment in the phosphorylation of MAPKs p38, ERK, and JNK; and mediation of the NFκB pathway via IκBα. Impaired gene expression and near abrogation in release of pro‐inflammatory cytokines TNF (p<0.0001), IL‐6 (p<0.0001), IL‐13 (p<0.0001), and chemokines CCL1 (p=0.0002), and CCL2 (p<0.0001) was detected. Finally, a significant inhibition of mast cell degranulation (p<0.0001), accompanied by an impairment in calcium mobilization, was observed in the TAK1‐inhibited cells. These results suggest that TAK1 acts as a signaling node, not only linking the MAPK and NFκB pathways in driving the late‐phase response, but also initiation of the degranulation mechanism of the mast cell early‐phase response following allergen recognition and may warrant consideration in future therapeutic development. Support or Funding Information: Funding: This work was supported by the Natural Sciences and Engineering Research Council (NSERC), the Canada Foundation for Innovation (CFI), the Ontario Research Fund (ORF), and Ontario Graduate Scholarships.

  • Open Access

    Interrupting reactivation of immunological memory reprograms allergy and averts anaphylaxis

    by Kelly Bruton, Paul Spill, Shabana Vohra, Owen Baribeau, Saba Manzoor, Siyon Gadkar, Malcolm Davidson, Tina D. Walker, Yosef Ellenbogen, Alexandra Florescu, et al.

    IgE production against innocuous antigens can lead to life-threatening reactions such as anaphylaxis. While IgE levels drastically decline with strict allergen avoidance, the ability to regenerate IgE can persist for a lifetime, as is the case for peanut allergy. The mechanism by which IgE regenerates remains unresolved. A novel culture system and application of single-cell RNA-sequencing, elucidated the transcriptomic signature of human peanut-reactive B and T cells and revealed IL-4/IL-13 as a signaling pathway critical for the IgE recall response. Indeed, interruption of this pathway not only prevented IgE production and anaphylaxis, but also reprogrammed the pathogenic response against peanut. This investigation advances our understanding of the mechanism that regenerates IgE in food allergy and spotlights IL-4/IL-13 blockade as a therapeutic with disease-transforming potential. One Sentence Summary: Single-cell transcriptomics of allergic memory responses reveals how to teach the immune system to forget.